In this article:

OTR Global Upgrades Illumina (ILMN) to Buy

In this article:
In this article:

In a report released yesterday, OTR Global from OTR Global upgraded Illumina (ILMNResearch Report) to Buy. The company’s shares closed last Tuesday at $357.35.

Illumina has an analyst consensus of Moderate Buy, with a price target consensus of $417.55.

See today’s best-performing stocks on TipRanks >>

Illumina’s market cap is currently $56.1B and has a P/E ratio of 70.85.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incorporated in 1998, Illumina, Inc. is a California-based company which develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The company’s products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting.

Read More on ILMN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed